Close
With a 10 to 20 year battery life*, Axonics F15 has redefined what it means to have a long-lived, recharge-free system.
10 to 20 year battery life *
Powered by NexCore™ Technology to deliver energy-efficient stimulation
Patients do not recharge
any system components
10cc in size
Thin, sleek design for patient comfort
Pocket-sized and intuitive patient Remote Control, with no recharging required
One-handed operation with no need for an extra communicator
Allows MR technician to check system readiness before full-body MRI
*Depending on therapy settings
InterStim™ is a registered trademark of Medtronic.
REFERENCES:
1. InterStim™ Systems: System eligibility, battery longevity, specifications manual. M988757A016 Rev B
2. InterStim X™ Product Manual: M016984C001 Rev C
IMPORTANT SAFETY INFORMATION:
Indications:
Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence (leakage) and significant symptoms of urgency-frequency, either alone or in combination. Axonics SNM Therapy for bowel control is indicated for the treatment of chronic fecal incontinence. The therapy should only be used in patients who have failed or are not candidates or could not tolerate more conservative treatments.
Contraindications:
Axonics SNM Therapy is contraindicated for patients who have not demonstrated an appropriate response to test stimulation or patients who are unable to operate the Axonics SNM Systems.
Warnings:
Implantation and use of the Axonics SNM Systems incurs risk beyond those normally associated with surgery, some of which may necessitate surgical intervention. These risks include, but are not limited to, adverse change in voiding function (bowel and/or bladder), infection, pain or irritation at the implant site, lead or device migration, electrical shock, change in sensation or magnitude of stimulation which has been described as uncomfortable (jolting or shocking) by some patients, and heating or burns at the device site.
Precautions:
The safety and effectiveness of the Axonics SNM Therapy has not been established for use in women who are pregnant or in delivery; for pediatric patients (under the age of 18 years for fecal incontinence and under the age of 16 years for overactive bladder and urinary retention); for patients with neurological diseases, such as multiple sclerosis or diabetes, or for bilateral stimulation.
Caution:
U.S. Federal law restricts this device to sale and use by, or on the order of, a physician.
For a complete listing of indications, contraindications, warnings and precautions, go to www.axonics.com/isi.
